We are monitoring the impact of COVID-19 on MEA Psoriasis Drugs Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Psoriasis Drugs Market Research Report - Segmented By Drug Type, Route of Administration, Target, & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - industry Analysis on Size, Share, Trends and Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1640
Pages: 140

MEA Psoriasis Drugs Market Size (2022 to 2027)

The Psoriasis Drugs Market size in the Middle East & Africa is expected to be worth USD 0.70 billion by 2027 from USD 0.49 billion in 2022, growing at a CAGR of 7.24% between 2022 2027.

Psoriasis can be caused by various conditions and disorders, including strep throat, cold, dry weather, wounds, scrapes, bug bites, severe sunburn, stress, smoking, and secondhand smoke, a family history of psoriasis, and high alcohol intake.

Due to a rise in psoriasis research and pipeline products and a growth in disease burden and demand for psoriasis therapies in emerging nations, the psoriasis drugs market in the MEA region is significantly growing. The expanding senior population is another primary driver promoting the psoriasis pharmaceutical industry, as the condition primarily affects the elderly. The rising incidence of psoriasis has fueled the growth of the psoriasis pharmaceuticals business by increasing the usage of various psoriatic pharmaceutical products and therapies across the Middle East and Africa.

The market growth in this region is further expected to accelerate due to an increase in psoriasis research and pipeline products and an increase in disease burden and demand for psoriasis treatments in emerging nations.

However, the market is expected to be limited by most available treatments' adverse effects and the high cost of therapy. Though drug efficacy supports market growth in treating the condition, negative market variables such as the high cost of psoriasis therapy may stifle market expansion.

This research report on the Middle East and Africa psoriasis drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

  • Pharmaceuticals
  • Biopharmaceuticals

By Route of Administration: 

  • Topical
  • Systemic
    • Oral
    • Intravenous
    • Others

By Target: 

  • Tumour Necrosis Factor (TNF)
  • Phosphodiesterase Type 4 (PDE4)
  • Interleukin

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

In 2020, MEA accounted for a moderate share in the worldwide market. However, growing favorable efforts from the governments and rising improvements in healthcare infrastructure are expected to change the scenario and accelerate the growth momentum of this regional market. Due to the high prevalence of psoriasis throughout the Middle East and Africa, the UAE occupied the leading share in the MEA market in 2020.

KEY MARKET PLAYERS:

Companies playing an active role in the MEA Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck, and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).

1.Introduction               

                1.1 Market Definition 

                1.2 Study Deliverables 

                1.3 Base Currency, Base Year and Forecast Periods       

                1.4 General Study Assumptions

2. Research Methodology

                2.1 Introduction            

                2.2 Research Phases   

        2.2.1 Secondary Research   

        2.2.2 Primary Research                 

        2.2.3 Econometric Modelling  

        2.2.4 Expert Validation                  

                2.3 Analysis Design      

                2.4 Study Timeline       

3. Overview

                3.1 Executive Summary

                3.2 Key Inferences      

                3.3 Epidemology           

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                 

                4.1 Market Drivers       

                4.2 Market Restraints 

                4.3 Key Challenges      

                4.4 Current Opportunities in the Market           

5. Market Segmentation   

                5.1 Drug Type

        5.1.1 Introduction                           

        5.1.2 Pharmaceuticals                   

        5.1.3 Biopharmaceuticals     

     5.2.3.1 Oral

     5.2.3.2 Intravenous

     5.2.3.3 Other

        5.1.4  Y-o-Y Growth Analysis, By Drug Type  

        5.1.5  Market Attractiveness Analysis, By Drug Type    

        5.1.6  Market Share Analysis, By Drug Type

                5.2 Route of Administration    

        5.2.1 Introduction   

        5.2.2 Topical  

        5.2.3 Systemic                  

        5.2.4  Y-o-Y Growth Analysis, By Route of Administration      

        5.2.5  Market Attractiveness Analysis, By Route of Administration    

        5.2.6  Market Share Analysis, By Route of Administration     

                5.3 Target        

        5.3.1 Introduction   

        5.3.2 Tumour Necrosis Factor (TNF)

        5.3.3 Phosphodiesterase Type 4 (PDE4)                

        5.3.4 Interleukin      

        5.3.5 Others  

        5.3.6  Y-o-Y Growth Analysis, By Target                 

        5.3.7  Market Attractiveness Analysis, By Target       

        5.3.8  Market Share Analysis, By Target                 

6. Geographical Analysis   

                6.1 Introduction            

        6.1.1 Regional Trends

        6.1.2 Impact Analysis 

        6.1.3 Y-o-Y Growth Analysis

             6.1.3.1 By Geographical Area     

             6.1.3.2 By Product           

             6.1.3.3 By Type 

             6.1.3.4 By Application    

             6.1.3.5 By Indication       

        6.1.4  Market Attractiveness Analysis 

             6.1.4.1 By Geographical Area     

             6.1.4.2 By Product           

             6.1.4.3 By Type 

             6.1.4.4 By Application    

             6.1.4.5 By Indication       

        6.1.5  Market Share Analysis  

             6.1.5.1 By Geographical Area     

             6.1.5.2 By Product           

             6.1.5.3 By Type 

             6.1.5.4 By Application    

             6.1.5.5 By Indication       

                6.2 Middle-East             

                6.3 Africa         

7.Strategic Analysis 

                7.1 PESTLE analysis      

        7.1.1 Political 

        7.1.2 Economic                 

        7.1.3 Social 

        7.1.4 Technological 

        7.1.5 Legal  

        7.1.6 Environmental   

                7.2 Porter’s Five analysis           

        7.2.1 Bargaining Power of Suppliers

        7.2.2 Bargaining Power of Consumers

                                7.2.3 Threat of New Entrants 

        7.2.4 Threat of Substitute Products and Services      

        7.2.5 Competitive Rivalry within the Industry 

8.Market Leaders' Analysis  

                8.1 Johnson & Johnson

        8.1.1 Overview                 

        8.1.2 Product Analysis                   

        8.1.3 Financial analysis                  

        8.1.4 Recent Developments   

        8.1.5 SWOT analysis   

        8.1.6 Analyst View  

                8.2 Novartis International AG

                8.3 Pfizer Inc  

                8.4 Merck and Co. Inc

                8.5 Celgene Corporation           

                8.6 Janssen Biotech Inc              

                8.7 Stiefel Laboratories Inc       

                8.8 Takeda Pharmaceutical Company Limited  

                8.9 Amgen      

                8.10 AbbVie    

9.Competitive Landscape 

                9.1 Market share analysis         

                9.2 Merger and Acquisition Analysis    

                9.3 Agreements, collaborations and Joint Ventures      

                9.4 New Product Launches      

10.Market Outlook and Investment Opportunities   

Appendix

                a) List of Tables

                b) List of Figures           

  1. Middle East & Africa Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  2. Middle East & Africa Oral Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  3. Middle East & Africa Intravenous Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  4. Middle East & Africa Others Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  5. Middle East Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  6. Africa Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample